001     182802
005     20240229145731.0
024 7 _ |a 10.1007/s00401-022-02516-2
|2 doi
024 7 _ |a pmid:36437415
|2 pmid
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:139077073
|2 altmetric
037 _ _ |a DKFZ-2022-02934
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Keck, Michaela-Kristina
|0 P:(DE-He78)9f1196ab1abb80483e1f69e8c0c4172d
|b 0
|e First author
|u dkfz
245 _ _ |a Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.
260 _ _ |a Heidelberg
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1673260745_23974
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B360#LA:B360# / 2023 Jan;145(1):49-69
520 _ _ |a Pediatric central nervous system (CNS) tumors represent the most common cause of cancer-related death in children aged 0-14 years. They differ from their adult counterparts, showing extensive clinical and molecular heterogeneity as well as a challenging histopathological spectrum that often impairs accurate diagnosis. Here, we use DNA methylation-based CNS tumor classification in combination with copy number, RNA-seq, and ChIP-seq analysis to characterize a newly identified CNS tumor type. In addition, we report histology, patient characteristics, and survival data in this tumor type. We describe a biologically distinct pediatric CNS tumor type (n = 31 cases) that is characterized by focal high-level amplification and resultant overexpression of either PLAGL1 or PLAGL2, and an absence of recurrent genetic alterations characteristic of other pediatric CNS tumor types. Both genes act as transcription factors for a regulatory subset of imprinted genes (IGs), components of the Wnt/β-Catenin pathway, and the potential drug targets RET and CYP2W1, which are also specifically overexpressed in this tumor type. A derived PLAGL-specific gene expression signature indicates dysregulation of imprinting control and differentiation/development. These tumors occurred throughout the neuroaxis including the cerebral hemispheres, cerebellum, and brainstem, and were predominantly composed of primitive embryonal-like cells lacking robust expression of markers of glial or neuronal differentiation (e.g., GFAP, OLIG2, and synaptophysin). Tumors with PLAGL1 amplification were typically diagnosed during adolescence (median age 10.5 years), whereas those with PLAGL2 amplification were diagnosed during early childhood (median age 2 years). The 10-year overall survival was 66% for PLAGL1-amplified tumors, 25% for PLAGL2-amplified tumors, 18% for male patients, and 82% for female patients. In summary, we describe a new type of biologically distinct CNS tumor characterized by PLAGL1/2 amplification that occurs predominantly in infants and toddlers (PLAGL2) or adolescents (PLAGL1) which we consider best classified as a CNS embryonal tumor and which is associated with intermediate survival. The cell of origin and optimal treatment strategies remain to be defined.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Molecular neuro-oncology
|2 Other
650 _ 7 |a PLAGL1
|2 Other
650 _ 7 |a PLAGL2
|2 Other
650 _ 7 |a Pediatric cancer
|2 Other
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 1
|u dkfz
700 1 _ |a Wittmann, Andrea
|0 P:(DE-He78)adf0bc22f6c87d09ddb939645a7870ed
|b 2
|u dkfz
700 1 _ |a Joshi, Piyush
|0 P:(DE-He78)ee036c22158d4b18f5228616af640355
|b 3
|u dkfz
700 1 _ |a Stichel, Damian
|0 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
|b 4
700 1 _ |a Beck, Pengbo
|0 P:(DE-He78)b8f2b74d0482aed61472c7065dc1ed56
|b 5
|u dkfz
700 1 _ |a Okonechnikow, Konstantin
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Sievers, Philipp
|0 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
|b 7
|u dkfz
700 1 _ |a Wefers, Annika K
|b 8
700 1 _ |a Roncaroli, Federico
|b 9
700 1 _ |a Avula, Shivaram
|b 10
700 1 _ |a McCabe, Martin G
|b 11
700 1 _ |a Hayden, James T
|b 12
700 1 _ |a Wesseling, Pieter
|b 13
700 1 _ |a Øra, Ingrid
|b 14
700 1 _ |a Nistér, Monica
|b 15
700 1 _ |a Kranendonk, Mariëtte E G
|b 16
700 1 _ |a Tops, Bastiaan B J
|b 17
700 1 _ |a Zapotocky, Michal
|b 18
700 1 _ |a Zamecnik, Josef
|b 19
700 1 _ |a Vasiljevic, Alexandre
|b 20
700 1 _ |a Fenouil, Tanguy
|b 21
700 1 _ |a Meyronet, David
|b 22
700 1 _ |a von Hoff, Katja
|b 23
700 1 _ |a Schüller, Ulrich
|b 24
700 1 _ |a Loiseau, Hugues
|b 25
700 1 _ |a Figarella-Branger, Dominique
|b 26
700 1 _ |a Kramm, Christof M
|b 27
700 1 _ |a Sturm, Dominik
|0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
|b 28
|u dkfz
700 1 _ |a Scheie, David
|b 29
700 1 _ |a Rauramaa, Tuomas
|b 30
700 1 _ |a Pesola, Jouni
|b 31
700 1 _ |a Gojo, Johannes
|b 32
700 1 _ |a Haberler, Christine
|b 33
700 1 _ |a Brandner, Sebastian
|b 34
700 1 _ |a Jacques, Tom
|b 35
700 1 _ |a Sexton Oates, Alexandra
|b 36
700 1 _ |a Saffery, Richard
|b 37
700 1 _ |a Koscielniak, Ewa
|b 38
700 1 _ |a Baker, Suzanne J
|b 39
700 1 _ |a Yip, Stephen
|b 40
700 1 _ |a Snuderl, Matija
|b 41
700 1 _ |a Ud Din, Nasir
|b 42
700 1 _ |a Samuel, David
|b 43
700 1 _ |a Schramm, Kathrin
|0 P:(DE-He78)2f592d9d8339bee07cca3956b7472b61
|b 44
|u dkfz
700 1 _ |a Blattner-Johnson, Mirjam
|0 P:(DE-He78)261d2b84aded878003e6e35d18113831
|b 45
|u dkfz
700 1 _ |a Selt, Florian
|0 P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e
|b 46
|u dkfz
700 1 _ |a Ecker, Jonas
|0 P:(DE-He78)3de637452ba900e2bdd359b8f41953bf
|b 47
|u dkfz
700 1 _ |a Milde, Till
|0 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
|b 48
|u dkfz
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 49
|u dkfz
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 50
|u dkfz
700 1 _ |a Perry, Arie
|b 51
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 52
|u dkfz
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 53
|u dkfz
700 1 _ |a Solomon, David A
|b 54
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 55
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00401-022-02516-2
|0 PERI:(DE-600)1458410-4
|n 1
|p 49-69
|t Acta neuropathologica
|v 145
|y 2023
|x 0001-6322
909 C O |p VDB
|o oai:inrepo02.dkfz.de:182802
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)9f1196ab1abb80483e1f69e8c0c4172d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)adf0bc22f6c87d09ddb939645a7870ed
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)ee036c22158d4b18f5228616af640355
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)b8f2b74d0482aed61472c7065dc1ed56
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 44
|6 P:(DE-He78)2f592d9d8339bee07cca3956b7472b61
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 45
|6 P:(DE-He78)261d2b84aded878003e6e35d18113831
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 46
|6 P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 47
|6 P:(DE-He78)3de637452ba900e2bdd359b8f41953bf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 48
|6 P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 49
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 50
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 52
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 53
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 55
|6 P:(DE-He78)551bb92841f634070997aa168d818492
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2022
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2022
|d 2023-10-21
920 2 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 0
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 0
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 3
920 1 _ |0 I:(DE-He78)B310-20160331
|k B310
|l KKE Pädiatrische Onkologie
|x 4
920 0 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)B310-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21